| Sep 23 |
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
|
| Sep 19 |
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
|
| Sep 19 |
4D Molecular data ‘bode well’ for eye gene therapy, but shares fall
|
| Sep 18 |
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
|
| Sep 5 |
4DMT Announces Presentations at Upcoming Retina Conferences
|
| Sep 3 |
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
|
| Aug 27 |
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
|
| Aug 23 |
4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
| Aug 12 |
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
|
| Aug 10 |
4D Molecular Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
